CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ORC2 (ImmuneEditome ID:4999)

1. Gene summary of enriched editing regions for ORC2

check button Gene summary
Gene informationGene symbol

ORC2

Gene ID

4999

GeneSynonymsORC2L
GeneCytomap

2q33.1

GeneTypeprotein-coding
GeneDescriptionorigin recognition complex subunit 2|origin recognition complex protein 2 homolog|origin recognition complex, subunit 2 homolog
GeneModificationdate20230517
UniprotIDQ13416;C9JK08;B8ZZ80
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:200909413-200910101:-ENST00000234296.5ENSG00000115942.7ORC2UTR3AluJr4,AluSzchr2:200909413-200910101:-.alignment
chr2:200914408-200917271:-ENST00000464147.1ENSG00000115942.7ORC2ncRNA_intronicAluSp,AluY,L1ME4c,AluSz,AluSz6,AluJochr2:200914408-200917271:-.alignment
chr2:200923338-200924329:-ENST00000464147.1ENSG00000115942.7ORC2ncRNA_intronicAluJr,AluSz,Tigger17achr2:200923338-200924329:-.alignment
chr2:200938128-200938921:-ENST00000474877.1ENSG00000115942.7ORC2ncRNA_intronicAluSp,AluSzchr2:200938128-200938921:-.alignment
chr2:200944656-200946312:-ENST00000467605.4ENSG00000115942.7ORC2ncRNA_intronicMER58A,L1M2,Helitron1Na_Mam,Charlie10,FLAM_C,AluJb,AluJrchr2:200944656-200946312:-.alignment


Top

2. Tumor-specific enriched editing regions for ORC2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:200909413-200910101:-BRCAEER4.6964e-09image
ENSG00000115942.7,ORC2BRCAEAG4.4254e-09image
chr2:200909413-200910101:-KICHEER4.8804e-03image
ENSG00000115942.7,ORC2KICHEAG4.8804e-03image
chr2:200909413-200910101:-LUSCEER8.4873e-03image
ENSG00000115942.7,ORC2LUSCEAG8.6917e-03image
chr2:200909413-200910101:-THCAEER1.2905e-04image
ENSG00000115942.7,ORC2THCAEAG1.2905e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000115942.7,ORC2COADPathEAG3.8280e-024.6960e-02-0.1018image
chr2:200909413-200910101:-COADPathEER3.3921e-024.4194e-02-0.1040image
chr2:200909413-200910101:-STADPathEER1.4228e-021.5047e-020.1360image
chr2:200909413-200910101:-THCAPathEER3.8672e-027.1698e-030.1202image
ENSG00000115942.7,ORC2THCAPathEAG3.8672e-027.1698e-030.1202image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr2:200909413-200910101:-LGGEER1.8985e-024.2509e-021.5475e-01image
ENSG00000115942.7,ORC2LGGEAG1.8985e-024.2509e-021.5475e-01image

Top

3. Enriched editing regions and immune related genes for ORC2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:200909413-200910101:-GBMEERENSG00000124193,SRSF6-0.48401.6274e-063.1487e-08-0.4227imageNNNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:200909413-200910101:-GBMEERENSG00000198429,ZNF69-0.46804.6471e-068.1943e-08-0.4109imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:200909413-200910101:-GBMEERENSG00000242615,CTC-359D24.3-0.45311.2460e-055.7810e-08-0.4153imageNNNAT_cells_follicular_helperGSVA_HALLMARK_HEME_METABOLISM
chr2:200909413-200910101:-GBMEERENSG00000275632,RP5-967N21.11-0.44691.4695e-051.8610e-07-0.4004imageNNNAT_cells_follicular_helperGSVA_HALLMARK_HEME_METABOLISM
chr2:200909413-200910101:-GBMEERENSG00000172878,METAP1D-0.44741.7177e-052.1857e-08-0.4271imageNNNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:200909413-200910101:-GBMEERENSG00000161547,SRSF2-0.43622.1128e-053.4882e-08-0.4215imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr2:200909413-200910101:-GBMEERENSG00000196345,ZKSCAN7-0.43543.2534e-054.5695e-09-0.4453imageNNNAMonocytesGSVA_HALLMARK_COAGULATION
chr2:200909413-200910101:-GBMEERENSG00000144559,TAMM41-0.40651.3111e-043.6368e-08-0.4210imageNNNAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr2:200909413-200910101:-GBMEERENSG00000115942,ORC2-0.37725.8215e-041.5831e-07-0.4025imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:200909413-200910101:-GBMEERENSG00000144161,ZC3H8-0.36529.0780e-041.5696e-07-0.4026imageNNZC3H8T_cells_follicular_helperGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for ORC2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:200909413-200910101:-
CESCEERA5ENSG00000121931.11chr1110949850:110950123:110952531:110952807:110951287:1109528070.15954.1636e-025.3656e-110.4119imageNNNAMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000115942.7,ORC2
CESCEAGA5ENSG00000121931.11chr1110949850:110950123:110952531:110952807:110951287:1109528070.15953.9990e-025.3656e-110.4119imageNACIN1;ADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr2:200909413-200910101:-
ESCAEERIRENSG00000204859.7chr16580540:6581299:6582057:6582223-0.41327.0395e-041.2766e-07-0.4077imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr2:200909413-200910101:-
MESOEERIRENSG00000142252.6chr1945079261:45079377:45079906:45080029-0.47554.5889e-029.9702e-05-0.4543imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr2:200909413-200910101:-
MESOEERMEXENSG00000108423.10chr1759860033:59860424:59863663:59863845:59866595:59866749:59878102:59878334-0.50604.5889e-026.2169e-07-0.5417imageNNNAMonocytesGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
ENSG00000115942.7,ORC2
MESOEAGIRENSG00000100445.12chr1424441291:24441795:24442097:24442177-0.47403.6509e-024.7268e-08-0.6403imageNAIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NAGSVA_HALLMARK_MITOTIC_SPINDLE
chr2:200909413-200910101:-
MESOEERIRENSG00000100445.12chr1424441291:24441795:24442097:24442177-0.47402.8115e-024.7268e-08-0.6403imageNNNAGSVA_HALLMARK_MITOTIC_SPINDLE
chr2:200909413-200910101:-
PCPGEERA3ENSG00000160752.10chr1155319610:155319688:155319870:155319928:155319856:1553199280.07304.7273e-025.0345e-160.6031imageNNNAPlasma_cellsGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000115942.7,ORC2
PCPGEAGA3ENSG00000160752.10chr1155319610:155319688:155319870:155319928:155319856:1553199280.07304.4370e-025.0345e-160.6031imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAPlasma_cellsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr2:200909413-200910101:-
STADEERA3ENSG00000204628.7chr5181239486:181239582:181238098:181238230:181238098:1812382390.05817.5364e-035.2319e-110.4081imageNNGNB2L1T_cells_CD4_memory_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for ORC2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:200909413-200910101:-ACCEERT_cells_CD4_memory_resting2.6531e-020.2731image
ENSG00000115942.7,ORC2ACCEAGT_cells_CD4_memory_resting2.6531e-020.2731image
chr2:200909413-200910101:-BLCAEERMacrophages_M05.3639e-040.1750image
ENSG00000115942.7,ORC2BLCAEAGMacrophages_M05.8332e-040.1738image
chr2:200909413-200910101:-BRCAEERT_cells_CD4_memory_activated3.0632e-050.1271image
ENSG00000115942.7,ORC2BRCAEAGT_cells_CD4_memory_activated2.7876e-050.1273image
chr2:200909413-200910101:-CESCEERT_cells_regulatory_(Tregs)1.3213e-02-0.1432image
ENSG00000115942.7,ORC2CESCEAGT_cells_regulatory_(Tregs)1.3213e-02-0.1432image
chr2:200909413-200910101:-COADEERMast_cells_activated8.2627e-03-0.1619image
ENSG00000115942.7,ORC2COADEAGMast_cells_activated1.0716e-02-0.1548image
ENSG00000115942.7,ORC2DLBCEAGT_cells_CD82.8624e-03-0.4256image
chr2:200909413-200910101:-ESCAEERMacrophages_M04.7915e-020.1571image
chr2:200914408-200917271:-ESCAEERB_cells_memory1.1577e-020.3732image
ENSG00000115942.7,ORC2ESCAEAGT_cells_CD4_memory_resting2.2854e-02-0.1799image
chr2:200909413-200910101:-GBMEERMonocytes2.4304e-020.1792image
ENSG00000115942.7,ORC2GBMEAGMonocytes2.4304e-020.1792image
chr2:200909413-200910101:-HNSCEERT_cells_regulatory_(Tregs)1.6810e-03-0.1504image
ENSG00000115942.7,ORC2HNSCEAGT_cells_regulatory_(Tregs)1.6810e-03-0.1504image
chr2:200909413-200910101:-KICHEEREosinophils7.7233e-030.3327image
ENSG00000115942.7,ORC2KICHEAGEosinophils7.7233e-030.3327image
chr2:200909413-200910101:-KIRCEERB_cells_naive1.5098e-020.1252image
ENSG00000115942.7,ORC2KIRCEAGB_cells_naive1.6805e-020.1231image
chr2:200909413-200910101:-KIRPEERNK_cells_resting6.3314e-030.1686image
ENSG00000115942.7,ORC2KIRPEAGNK_cells_resting6.0608e-030.1695image
chr2:200909413-200910101:-LUADEERT_cells_CD4_memory_activated2.9892e-030.1335image
ENSG00000115942.7,ORC2LUADEAGT_cells_CD4_memory_activated2.3544e-030.1356image
chr2:200909413-200910101:-MESOEERMast_cells_resting2.3388e-02-0.2549image
ENSG00000115942.7,ORC2MESOEAGMast_cells_resting2.3388e-02-0.2549image
chr2:200909413-200910101:-OVEERT_cells_CD89.9500e-040.1940image
ENSG00000115942.7,ORC2OVEAGT_cells_CD81.4325e-030.1880image
chr2:200909413-200910101:-PCPGEERPlasma_cells3.1260e-040.2657image
ENSG00000115942.7,ORC2PCPGEAGPlasma_cells3.1260e-040.2657image
chr2:200909413-200910101:-PRADEERT_cells_CD4_naive3.5975e-03-0.1304image
ENSG00000115942.7,ORC2PRADEAGT_cells_CD4_naive3.7719e-03-0.1296image
chr2:200909413-200910101:-READEERMacrophages_M12.1629e-020.2380image
ENSG00000115942.7,ORC2READEAGMacrophages_M12.1629e-020.2380image
chr2:200909413-200910101:-SARCEERT_cells_CD4_memory_activated4.4710e-030.1844image
ENSG00000115942.7,ORC2SARCEAGT_cells_CD4_memory_activated4.4680e-030.1845image
chr2:200909413-200910101:-SKCMEERNK_cells_activated1.1211e-020.1212image
ENSG00000115942.7,ORC2SKCMEAGNK_cells_activated1.1211e-020.1212image
chr2:200909413-200910101:-STADEERT_cells_CD4_memory_activated2.3106e-040.1990image
chr2:200914408-200917271:-STADEERB_cells_memory1.1627e-020.2709image
ENSG00000115942.7,ORC2STADEAGT_cells_CD4_memory_activated8.5554e-040.1795image
chr2:200909413-200910101:-TGCTEERNeutrophils1.0347e-040.3068image
ENSG00000115942.7,ORC2TGCTEAGNeutrophils1.0347e-040.3068image
chr2:200909413-200910101:-THCAEERDendritic_cells_activated6.2606e-030.1221image
ENSG00000115942.7,ORC2THCAEAGDendritic_cells_activated6.2606e-030.1221image
chr2:200909413-200910101:-THYMEERMacrophages_M06.6305e-050.3662image
ENSG00000115942.7,ORC2THYMEAGMacrophages_M01.6864e-040.3452image
chr2:200909413-200910101:-UCECEERT_cells_regulatory_(Tregs)2.1985e-02-0.1783image
ENSG00000115942.7,ORC2UCECEAGNK_cells_activated4.4093e-02-0.1542image
chr2:200909413-200910101:-UCSEERB_cells_naive4.6579e-03-0.3728image
ENSG00000115942.7,ORC2UCSEAGB_cells_naive4.6579e-03-0.3728image


Top

6. Enriched editing regions and immune gene sets for ORC2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000115942.7,ORC2BRCAEAG2.0529e-050.12941.7562e-050.13045.9857e-030.08371.1199e-020.0773image
chr2:200909413-200910101:-BRCAEER5.7498e-060.13821.4262e-050.13232.8330e-030.09126.2304e-030.0836image
ENSG00000115942.7,ORC2LUADEAG2.6285e-040.16241.8854e-030.13852.2470e-020.10203.4440e-050.1839image
chr2:200909413-200910101:-LUADEER2.9274e-040.16241.8539e-030.13982.0064e-020.10474.1534e-050.1835image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr2:200909413-200910101:-ACCGSVA_HALLMARK_DNA_REPAIREER1.2691e-02-0.3053image
ENSG00000115942.7,ORC2ACCGSVA_HALLMARK_DNA_REPAIREAG1.2691e-02-0.3053image
ENSG00000115942.7,ORC2BLCAGSVA_HALLMARK_HYPOXIAEAG5.4530e-040.1747image
chr2:200909413-200910101:-BLCAGSVA_HALLMARK_HYPOXIAEER4.6634e-040.1768image
chr2:200909413-200910101:-BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER2.2181e-140.2307image
ENSG00000115942.7,ORC2BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.3692e-130.2229image
chr2:200909413-200910101:-CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.5271e-060.2645image
ENSG00000115942.7,ORC2CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.5271e-060.2645image
chr2:200909413-200910101:-COADGSVA_HALLMARK_APOPTOSISEER7.5249e-040.2058image
ENSG00000115942.7,ORC2COADGSVA_HALLMARK_APOPTOSISEAG3.8760e-050.2472image
ENSG00000115942.7,ORC2DLBCGSVA_HALLMARK_HYPOXIAEAG1.7632e-030.4442image
ENSG00000115942.7,ORC2ESCAGSVA_HALLMARK_P53_PATHWAYEAG1.7091e-030.2461image
chr2:200914408-200917271:-ESCAGSVA_HALLMARK_UV_RESPONSE_DNEER1.2553e-020.3692image
chr2:200909413-200910101:-ESCAGSVA_HALLMARK_P53_PATHWAYEER4.5743e-040.2747image
chr2:200909413-200910101:-GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.1896e-050.3308image
ENSG00000115942.7,ORC2GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.1896e-050.3308image
ENSG00000115942.7,ORC2HNSCGSVA_HALLMARK_COAGULATIONEAG1.5571e-070.2486image
chr2:200909413-200910101:-HNSCGSVA_HALLMARK_COAGULATIONEER1.5571e-070.2486image
chr2:200909413-200910101:-KIRCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.1478e-040.1976image
ENSG00000115942.7,ORC2KIRCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.9053e-040.1910image
chr2:200909413-200910101:-KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER3.0395e-020.1340image
ENSG00000115942.7,ORC2KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.8781e-020.1354image
ENSG00000115942.7,ORC2LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG9.0973e-110.2782image
chr2:200909413-200910101:-LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER9.0973e-110.2782image
chr2:200909413-200910101:-LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.3276e-030.2000image
ENSG00000115942.7,ORC2LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG8.5534e-040.2071image
chr2:200909413-200910101:-LUADGSVA_HALLMARK_UV_RESPONSE_UPEER2.5052e-070.2297image
ENSG00000115942.7,ORC2LUADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.5886e-070.2277image
ENSG00000115942.7,ORC2LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8955e-030.1422image
chr2:200909413-200910101:-LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0204e-030.1413image
chr2:200909413-200910101:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.5131e-030.3511image
ENSG00000115942.7,ORC2MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.5131e-030.3511image
ENSG00000115942.7,ORC2OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.0333e-070.3088image
chr2:200909413-200910101:-OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.5601e-070.3046image
ENSG00000115942.7,ORC2PAADGSVA_HALLMARK_DNA_REPAIREAG1.4183e-02-0.1856image
chr2:200909413-200910101:-PAADGSVA_HALLMARK_DNA_REPAIREER1.4183e-02-0.1856image
ENSG00000115942.7,ORC2PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.7538e-02-0.1769image
chr2:200909413-200910101:-PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.7538e-02-0.1769image
ENSG00000115942.7,ORC2PRADGSVA_HALLMARK_HYPOXIAEAG1.6177e-040.1683image
chr2:200909413-200910101:-PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.3505e-040.1643image
ENSG00000115942.7,ORC2READGSVA_HALLMARK_COMPLEMENTEAG2.7860e-030.3067image
chr2:200909413-200910101:-READGSVA_HALLMARK_COMPLEMENTEER2.7860e-030.3067image
chr2:200909413-200910101:-SARCGSVA_HALLMARK_HYPOXIAEER4.5211e-030.1842image
ENSG00000115942.7,ORC2SARCGSVA_HALLMARK_HYPOXIAEAG4.5077e-030.1843image
ENSG00000115942.7,ORC2SKCMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.1119e-040.1838image
chr2:200909413-200910101:-SKCMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.1119e-040.1838image
chr2:200909413-200910101:-STADGSVA_HALLMARK_COMPLEMENTEER2.9142e-070.2746image
ENSG00000115942.7,ORC2STADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.5102e-100.3335image
chr2:200944656-200946312:-STADGSVA_HALLMARK_APICAL_SURFACEEER2.1692e-020.2431image
ENSG00000115942.7,ORC2TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.4561e-020.1699image
chr2:200909413-200910101:-TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.4561e-020.1699image
chr2:200909413-200910101:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.3732e-060.2092image
ENSG00000115942.7,ORC2THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.3732e-060.2092image
chr2:200909413-200910101:-THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.9042e-030.2890image
ENSG00000115942.7,ORC2THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.2864e-030.2979image
ENSG00000115942.7,ORC2UCECGSVA_HALLMARK_DNA_REPAIREAG1.0750e-02-0.1946image
chr2:200909413-200910101:-UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.8853e-030.2306image
chr2:200909413-200910101:-UCSGSVA_HALLMARK_APOPTOSISEER1.2431e-030.4207image
ENSG00000115942.7,ORC2UCSGSVA_HALLMARK_APOPTOSISEAG1.2431e-030.4207image


Top

7. Enriched editing regions and drugs for ORC2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000115942.7,ORC2ACCLFM.A13EAG1.1752e-02-0.3084image
chr2:200909413-200910101:-ACCLFM.A13EER1.1752e-02-0.3084image
chr2:200909413-200910101:-BLCACMKEER1.2808e-04-0.1932image
ENSG00000115942.7,ORC2BLCACMKEAG1.2612e-04-0.1934image
ENSG00000115942.7,ORC2BRCACGP.082996EAG1.1910e-05-0.1330image
chr2:200909413-200910101:-BRCAJW.7.52.1EER2.6834e-06-0.1430image
chr2:200909413-200910101:-CESCCI.1040EER2.9166e-04-0.2081image
ENSG00000115942.7,ORC2CESCCI.1040EAG2.9166e-04-0.2081image
chr2:200909413-200910101:-CHOLFH535EER2.7862e-020.3829image
ENSG00000115942.7,ORC2CHOLFH535EAG2.7862e-020.3829image
chr2:200909413-200910101:-COADAICAREER1.0392e-03-0.2004image
ENSG00000115942.7,ORC2COADKU.55933EAG5.8954e-04-0.2074image
ENSG00000115942.7,ORC2DLBCBosutinibEAG6.6661e-030.3945image
ENSG00000115942.7,ORC2ESCAFTI.277EAG2.9844e-07-0.3919image
chr2:200909413-200910101:-ESCAFTI.277EER1.6772e-04-0.2941image
chr2:200914408-200917271:-ESCAAZD6482EER1.5312e-04-0.5350image
chr2:200909413-200910101:-GBMCamptothecinEER6.8015e-050.3114image
ENSG00000115942.7,ORC2GBMCamptothecinEAG6.8015e-050.3114image
ENSG00000115942.7,ORC2HNSCLFM.A13EAG1.1347e-06-0.2311image
chr2:200909413-200910101:-HNSCLFM.A13EER1.1347e-06-0.2311image
chr2:200909413-200910101:-KICHAZD8055EER1.1448e-030.4005image
ENSG00000115942.7,ORC2KICHAZD8055EAG1.1448e-030.4005image
ENSG00000115942.7,ORC2KIRCEHT.1864EAG6.3202e-030.1406image
chr2:200909413-200910101:-KIRCCMKEER6.4273e-03-0.1403image
ENSG00000115942.7,ORC2KIRPIPA.3EAG3.0316e-040.2219image
chr2:200909413-200910101:-KIRPIPA.3EER2.9099e-040.2225image
chr2:200909413-200910101:-LGGDMOGEER1.0385e-05-0.1913image
ENSG00000115942.7,ORC2LGGDMOGEAG1.0385e-05-0.1913image
ENSG00000115942.7,ORC2LIHCGSK.650394EAG1.0846e-030.2031image
chr2:200909413-200910101:-LIHCGSK.650394EER1.3358e-030.1999image
ENSG00000115942.7,ORC2LUADCHIR.99021EAG2.7708e-030.1337image
chr2:200909413-200910101:-LUADCHIR.99021EER3.4216e-030.1319image
chr2:200909413-200910101:-LUSCAUY922EER4.2986e-04-0.1609image
ENSG00000115942.7,ORC2LUSCAUY922EAG3.7978e-04-0.1624image
chr2:200909413-200910101:-MESOEHT.1864EER1.2277e-020.2805image
ENSG00000115942.7,ORC2MESOEHT.1864EAG1.2277e-020.2805image
chr2:200909413-200910101:-OVBMS.509744EER1.7709e-04-0.2203image
ENSG00000115942.7,ORC2OVBMS.509744EAG1.6011e-04-0.2218image
chr2:200909413-200910101:-PAADLFM.A13EER1.2239e-050.3248image
ENSG00000115942.7,ORC2PAADLFM.A13EAG1.2239e-050.3248image
ENSG00000115942.7,ORC2PCPGAZD6482EAG5.4398e-030.2064image
chr2:200909413-200910101:-PCPGAZD6482EER5.4398e-030.2064image
chr2:200909413-200910101:-PRADEpothilone.BEER6.5113e-050.1782image
ENSG00000115942.7,ORC2PRADEpothilone.BEAG1.4360e-040.1696image
chr2:200909413-200910101:-READDMOGEER2.5447e-03-0.3094image
ENSG00000115942.7,ORC2READDMOGEAG2.5447e-03-0.3094image
chr2:200909413-200910101:-SARCMG.132EER6.7539e-04-0.2197image
ENSG00000115942.7,ORC2SARCMG.132EAG6.7351e-04-0.2198image
ENSG00000115942.7,ORC2SKCMGNF.2EAG1.7423e-03-0.1494image
chr2:200909413-200910101:-SKCMGNF.2EER1.7423e-03-0.1494image
chr2:200909413-200910101:-STADKU.55933EER1.5457e-03-0.1716image
ENSG00000115942.7,ORC2STADEmbelinEAG5.3626e-05-0.2166image
chr2:200914408-200917271:-STADAMG.706EER2.8395e-04-0.3820image
chr2:200909413-200910101:-TGCTDoxorubicinEER3.9576e-030.2302image
ENSG00000115942.7,ORC2TGCTDoxorubicinEAG3.9576e-030.2302image
ENSG00000115942.7,ORC2THCABMS.708163EAG8.5071e-07-0.2181image
chr2:200909413-200910101:-THCABMS.708163EER8.5071e-07-0.2181image
ENSG00000115942.7,ORC2THYMGW.441756EAG7.9745e-06-0.4047image
chr2:200909413-200910101:-THYMGW.441756EER4.6295e-06-0.4159image
ENSG00000115942.7,ORC2UCECCytarabineEAG9.6939e-030.1973image
chr2:200909413-200910101:-UCECDocetaxelEER1.5645e-040.2902image
chr2:200909413-200910101:-UCSBryostatin.1EER2.8030e-03-0.3921image
ENSG00000115942.7,ORC2UCSBryostatin.1EAG2.8030e-03-0.3921image
chr2:200909413-200910101:-UVMBMS.536924EER4.9004e-02-0.2692image
ENSG00000115942.7,ORC2UVMBMS.536924EAG4.9004e-02-0.2692image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType